{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:10:33Z","timestamp":1760188233152,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1016\/j.jaci.2003.08.001","type":"journal-article","created":{"date-parts":[[2003,10,16]],"date-time":"2003-10-16T11:11:48Z","timestamp":1066302708000},"page":"675-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combating high-priority biological agents"],"prefix":"10.1016","volume":"112","author":[{"given":"Rebecca S","family":"Gruchalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1977","series-title":"US Army activity in the U.S. biological warfare programs","author":"US Army","key":"10.1016\/j.jaci.2003.08.001_BIB1"},{"key":"10.1016\/j.jaci.2003.08.001_BIB2","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1001\/jama.283.17.2281","article-title":"Plague as a biological weaponmedical and public health management","volume":"283","author":"Inglesby","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weaponmedical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB4","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB5","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1001\/jama.285.21.2763","article-title":"Tularemia as a biological weaponmedical and public health management","volume":"285","author":"Dennis","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3201\/eid0802.010164","article-title":"Public health assessment of potential biological terrorism agentsreport summary","volume":"8","author":"Rotz","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaci.2003.08.001_BIB7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1067\/mai.2002.121947","article-title":"Bioterrorism: relevance to allergy and immunology in clinical practice","volume":"109","author":"Fritz","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB8","first-page":"33","article-title":"Anthrax vaccines","volume":"271","author":"Friedlander","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jaci.2003.08.001_BIB10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.jom.0000058345.05741.6b","article-title":"Analysis of adverse events after anthrax immunization in US Army medical personnel","volume":"45","author":"Wasserman","year":"2003","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB11","doi-asserted-by":"crossref","unstructured":"Joellenbeck L, Zwanziger L, Durch J, Stroms B. The anthrax vaccine: is it safe? Washington, DC: National Academy Press; 2002. p. 1-32, 56-82.","DOI":"10.21236\/ADA403352"},{"key":"10.1016\/j.jaci.2003.08.001_BIB12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.287.12.1556","article-title":"Relationship between pregnancy and anthrax vaccination and pregnancy and birth outcomes among US Army women","volume":"287","author":"Wiessen","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB13","first-page":"217","article-title":"Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios","volume":"20","author":"Geier","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1378\/chest.122.2.741","article-title":"Hypersensitivity pneumonitis following anthrax vaccination","volume":"122","author":"Timmer","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2003.08.001_BIB15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2466\/pr0.2002.90.2.639","article-title":"Self-reported changes in subjective health and anthrax vaccination as reported by over 900 Persian Gulf War era veterans","volume":"90","author":"Schumm","year":"2002","journal-title":"Psychol Rep"},{"key":"10.1016\/j.jaci.2003.08.001_BIB16","first-page":"909","article-title":"Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001","volume":"50","author":"CDC","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rev"},{"key":"10.1016\/j.jaci.2003.08.001_BIB17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaci.2003.08.001_BIB18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/ajhp\/59.12.1189","article-title":"2001 anthrax crisis in Washington, DC: clinic for persons exposed to contaminated mail","volume":"59","author":"Haffer","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaci.2003.08.001_BIB19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0378-4274(01)00509-4","article-title":"Clinical toxicological aspects of fluoroquinolones","volume":"127","author":"Stahlmann","year":"2002","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.jaci.2003.08.001_BIB20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-122-5-199503010-00026","article-title":"Anaphylactoid reactions to ciprofloxacin","volume":"122","author":"Assouad","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0091-6749(95)70240-7","article-title":"Ciprofloxacin desensitization in a patient with cystic fibrosis","volume":"96","author":"Lantner","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0091-6749(96)70218-X","article-title":"Ciprofloxacin desensitization","volume":"97","author":"Gea-Banacloche","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archderm.1997.03890460044005","article-title":"Comparative safety of tetracycline, minocycline, and doxycycline","volume":"133","author":"Shapiro","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB24","first-page":"577","article-title":"Recurrent erythema multiforme following successive treatments with tetracyclines: apropos of a case","volume":"38","author":"Albengres","year":"1983","journal-title":"Therapie"},{"key":"10.1016\/j.jaci.2003.08.001_BIB25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2230.1988.tb00690.x","article-title":"Erythema multiforme occurring in association with lupus erythmatosis during therapy with doxycycline","volume":"13","author":"Lewis-Jones","year":"1988","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2230.1987.tb01879.x","article-title":"Stevens-Johnson syndrome due to tetracyclines: a case report (doxycycline) and review of the literature","volume":"12","author":"Curley","year":"1987","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB27","series-title":"Allergy: principles and practice","first-page":"1726","article-title":"Drug allergy","author":"Sullivan","year":"1993"},{"key":"10.1016\/j.jaci.2003.08.001_BIB28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1081-1206(10)62890-6","article-title":"Disease management of drug hypersensitivity: a practice parameter","volume":"83","author":"Bernstein","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB29","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1001\/jama.281.22.2127","article-title":"Smallpox as a biological weaponmedical and public health management","volume":"281","author":"Henderson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(03)00008-1","article-title":"Pathogenesis and potential antiviral therapy of complications of smallpox vaccination","volume":"58","author":"Bray","year":"2003","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jaci.2003.08.001_BIB31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1067\/mai.2002.128052","article-title":"Smallpox vaccination: Risk considerations for patients with atopic dermatitis","volume":"110","author":"Engler","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"RR-4","key":"10.1016\/j.jaci.2003.08.001_BIB32","first-page":"1","article-title":"Smallpox vaccination and adverse reactions: guidance for clinicians","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR."},{"key":"10.1016\/j.jaci.2003.08.001_BIB33","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.288.15.1901","article-title":"Contact vaccinia-Transmission of vaccinia from smallpox vaccination","volume":"288","author":"Neff","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2003.08.001_BIB34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968: National surveillance in the United States","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB36","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/0002-9343(84)90988-4","article-title":"Equine antitoxin use and other factors that predict outcome in type A foodborne botulism","volume":"76","author":"Tacket","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(80)90469-6","article-title":"Hypersensitivity reactions associated with botulinal antitoxin","volume":"69","author":"Black","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum toxin therapy: neutralizing and nonneutralizing antibodiestherapeutic consequences","volume":"147","author":"Goeschel","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jaci.2003.08.001_BIB39","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archinte.1992.00400180107017","article-title":"Plague: a clinical review of 27 cases","volume":"152","author":"Crook","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2003.08.001_BIB40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0021-8707(70)90061-4","article-title":"Allergic reactions due to plague vaccine","volume":"46","author":"Reisman","year":"1970","journal-title":"J Allergy"},{"key":"10.1016\/j.jaci.2003.08.001_BIB41","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/129.Supplement_1.S19","article-title":"Plague immunization. II. Relation of adverse reactions to multiple immunizations with killed vaccine","volume":"129","author":"Marshall","year":"1974","journal-title":"J Infect Dis."},{"key":"10.1016\/j.jaci.2003.08.001_BIB42","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/infdis\/129.Supplement_1.S30","article-title":"Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffkine and freeze-dried plague vaccine","volume":"129","author":"Meyer","year":"1974","journal-title":"J Infect Dis."}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674903020293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674903020293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:50:15Z","timestamp":1758775815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674903020293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S0091674903020293"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2003.08.001","relation":{},"ISSN":["0091-6749"],"issn-type":[{"type":"print","value":"0091-6749"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combating high-priority biological agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2003.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}